A bivalent antihypertensive vaccine targeting L‐type calcium channels and angiotensin AT₁ receptors

Abstract

Immunotherapy against both AT₁ receptors and Ca_V 1.2 channels decreased the BP in hypertensive rodents effectively and provided protection against hypertensive target organ damage without obvious feedback activation of renin-angiotensin system or induction of dominant antibodies against the carrier protein. Thus, the HBcAg-CE12-CQ10 vaccine may provide a novel and promising therapeutic approach for hypertension.